Lacipil (Lacidipine)

Lacidipine blocks L‑type calcium channels in the smooth muscle of blood vessels. By preventing calcium entry, it relaxes the arterial walls, causing vasodilation and a decrease in peripheral resistance, which lowers systemic blood pressure.

The appropriate dose of Lacipil is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and any concomitant medications. Dosage adjustments are made individually and should follow the prescriber’s instructions.

The safety of lacidipine in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Lacipil, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lacidipine belongs to the dihydropyridine class of calcium‑channel blockers, offering once‑daily dosing and a favorable vascular selectivity profile. Compared with beta‑blockers or ACE inhibitors, it primarily reduces peripheral resistance without directly affecting heart rate, making it a useful alternative or add‑on therapy.

Lacipil tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Lacipil is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events, although rare, include severe hypotension, angio‑edema, and hepatic dysfunction. Patients should seek immediate medical attention if they experience sudden dizziness, swelling of the face or throat, or signs of liver injury such as jaundice.

Lacipil is contraindicated in patients with known hypersensitivity to lacidipine or any component of the formulation, and in those with severe aortic stenosis or uncontrolled heart failure. Clinicians should also exercise caution in patients with significant liver disease.